
|Articles|December 26, 2005
Compounders urge FDA to reject Wyeth petition
Advertisement
The International Academy of Compounding Pharmacy (IACP) has urged the FDA to reject Wyeth's citizen's petition to place restrictions on compounded bioequivalent hormone replacement therapy (BHRT). The petition "does not aim to protect women's health, just Wyeth's wealth," by trying to impose far-ranging restrictions on physicians' ability to prescribe and pharmacists' ability to compound BHRT, contended IACP executive director L. D. King.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Expert Addresses Pharmacy’s Uncertainty Amid MFN Drug Pricing Policy
2
Q&A: How Complex US Drug Market Impedes MFN Pricing Policy
3
Why Trump’s Second Term Is Different for the MFN Drug Pricing Policy
4
Variation in Insulin Pump Options Creates Opportunity for Pharmacist Counseling | ASHP Midyear 2025
5























































































































